Bromodomains a New Class of Epigenetic Targets Ripe for Small Molecule Drug Discovery
Dr Jason WITHERINGTON
GLAXOSMITHKLINE R&D, Stevenage, United Kingdom
Validation of N-Myristoyltransferase as a Drug Target
Prof. Paul WYATT
UNIVERSITY OF DUNDEE, Dundee, United Kingdom
Accelerated C-H Activation Reactions: Enantioselectivity and Positional Selectivity
Prof Jin-Quan YU
THE SCRIPPS RESEARCH INSTITUTE, La Jolla, United States
Selected Oral Communications
Small Molecule Inhibitors of the Neuropilin-1 VEGF-A Interaction
Dr Philip FALLON
DOMAINEX, Saffron Walden, United Kingdom
Halogen Bonding in Protein–ligand Interactions
Mr Leo HARDEGGER
ETH ZURICH, Zürich, Switzerland
The Chemical Biology Consortium-
and Experimental Therapeutics Program
Dr Sanjay MALHOTRA
NATIONAL CANCER INSTITUTE, Frederick, United States
Adventures in Medicinal Chemistry and Knowledge Capture
Dr Alexander MAYWEG
F. HOFFMANN-LA ROCHE LTD, BASEL, Switzerland
Identification of Bisaryloxy Azetidine Urea Derivatives as Fatty Acid Amide Hydrolase Inhibitors
Dr Hans MEISSNER
VERNALIS, Winnersh, United Kingdom
Identification of Leads from the Tres Cantos Antimalarial Set: Cyclopropyl Carboxamides Show Good Oral Bioavailability and Efficacy In Malarial Animal Models
Mrs Maria Lourdes RUEDA-BENEDE
GLAXOSMITHKLINE, Tres Cantos, Spain
Highly Efficient Catalytic System for C-H Activation: A Novel and Practical Synthesis of Angiotensin II Receptor Blockers
Dr Masahiko SEKI
MITSUBISHI TANABE PHARMA CORPORATION, Fukuoka, Japan
The Grandisine Alkaloids as Selective δ-Opioid Receptor Agonists; When is a Natural Product not a Natural Product?
Prof. Richard TAYLOR
UNIVERSITY OF YORK, York, United Kingdom Read more